NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Organon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

Core Insights - Organon & Co. is a global healthcare company with a portfolio of over 70 medicines and products, having spun off from Merck & Co. in June 2021 [1] Company Overview - The company has been experiencing fluctuations in its stock price since the spin-off from Merck & Co. [1] Investment Focus - The investment strategy focuses on value-oriented opportunities, particularly in sectors such as chemicals, homebuilders, building materials, industrials, and metals & mining [1] - The preference is for stocks that are undervalued and have potential catalysts in the near future, with an investment horizon ranging from one quarter to two years [1]

Investors might want to bet on Organon (OGN) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors often find ...

Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimat ...

Organon (OGN) ended the recent trading session at $10.19, demonstrating a +1.49% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.94%. Elsewhere, the Dow saw an upswing of 0.75%, while the tech-heavy Nasdaq appreciated by 1.52%. The pharmaceutical company's stock has climbed by 11.06% in the past month, exceeding the Medical sector's gain of 4.95% and the S&P 500's gain of 1.67%.The investment community will be closely monitoring the performance o ...

Core Viewpoint - A lawsuit has been filed against Organon & Co. and certain senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, captioned Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided a healthy dividend to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a severe cut in its dividend [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4].

SAN DIEGO, June 16, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon as well as certain of Organon's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Organon class action lawsuit, please provide y ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in stock price [1][2]. Group 1: Allegations and Impact - The class period for the allegations is from October 31, 2024, to April 30, 2025 [2]. - Defendants allegedly provided positive statements while concealing material adverse facts about Organon's capital allocation priorities, particularly regarding a debt reduction strategy after the acquisition of Dermavant [2]. - Following the announcement of a 70% decrease in the regular quarterly dividend, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in one day [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of July 22, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided dividends to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority," but later shifted focus to debt reduction [3]. - On May 1, 2025, Organon announced a drastic cut in its dividend payout from $0.28 per share to $0.02 per share, leading to a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].